

Clinical Chemistry

Copy of e-mail notification

zcy2170

Your article (tracking # 262824) from Clinical Chemistry is available for download

Dear Author,

Please read this entire e-mail for important instructions regarding your paper.

The proof for your article to be published in "Clinical Chemistry" is available for download. Please refer to this URL address

<http://rapidproof.cadmus.com/RapidProof/retrieval/index.jsp>

Login: your E-mail address

Password: sSyeu5AYfQzo

If you have trouble downloading the file, please contact Cathy Montgomery:
cathy.montgomery@cenveo.com.

The site contains 1 file. You will need to have Adobe Acrobat® Reader software to read these files. This is free software and is available at <http://www.adobe.com/products/acrobat/readstep.html>.

The file contains:

Proofreading Marks Guide

Reprint Order Form

A copy of the Early Release version of the page proof for your article

After downloading the PDF file, please read the page proof carefully and:

- 1) indicate changes or corrections in the PDF proof using the built in commenting tools provided;
- 2) answer all queries (footnotes A, B, C, etc.) on the last page of the PDF proof;
- 3) proofread any tables and equations carefully;
- 4) check that all symbols (Greek letters, etc) have translated correctly.

WITHIN 48 HOURS, please return the following items to the email address given below:

- 1) Annotated PDF
- 2) If CORRECTIONS are needed to figures, please send replacement files electronically
- 3) Reprint Order Forms

The corrected proof and accompanying materials should be e-mailed to:

ScholarOne, a Thomson Reuters business

Attn: Russell Talbert

Email: russell.talbert@thomsonreuters.com

EARLY RELEASE: Please note that this version of your paper will be published electronically under Clinical Chemistry's Early Release policy. Your edits will NOT be included in the Early Release version but will be incorporated when the full issue is finalized. If there are serious scientific errors present in this version, please indicate this when you return your corrections, though we cannot guarantee at this time that changes will be made prior to online publication.

IF YOUR ARTICLE CONTAINS COLOR and you wish to order reprints, it is critical that you return the Reprint Order Form immediately.

If you have any problems or questions concerning the manuscript, please contact:

Russell Talbert
Composition Services Project Manager
ScholarOne, a Thomson Reuters business
Email: russell.talbert@thomsonreuters.com
Phone: +1 502-724-5805

Clinical Chemistry 2017

This is your reprint order form or pro forma invoice

(Please keep a copy of this document for your records.)

Reprint order forms and purchase orders or prepayments must be received 72 hours after receipt of form either by mail or email only - cjsreprints@cadmus.com. It is the policy of Cenveo Reprints to issue one invoice per order when possible.

Please print clearly. Please return this form whether reprints are ordered or not.

Author Name _____
Title of Article _____
Issue of Journal _____ Reprint # **3959303** Manuscript # **262824** Publication Date _____
Number of Pages **7** Color in Article? Yes / No (Please Circle) Symbol **CC**

Please include the journal name and reprint number or manuscript number on your purchase order or other correspondence.

Order and Shipping Information

Reprint Costs (Please see page 2 of 2 for reprint costs/fees.)

_____ No. of reprints ordered \$ _____
_____ No. of color reprints ordered \$ _____
_____ No. of covers black ordered \$ _____
_____ No. of covers 2-color ordered \$ _____
Less AACC Members 20% Discount \$ - _____
AACC Member # _____

Subtotal \$ _____

Taxes \$ _____

(Add appropriate sales tax for Virginia, Maryland, Pennsylvania, and the District of Columbia or Canadian GST to the reprints if your order is to be shipped to these locations.)

First address included, add \$32 for
each additional shipping address \$ _____

Total Amount Due \$ _____

Shipping Address (cannot ship to a P.O. Box) Please Print Clearly

Name _____
Institution _____
Street _____
City _____ State _____ Zip _____
Country _____
Quantity _____ Fax _____
Phone: Day _____ Evening _____
E-mail Address _____

Additional Shipping Address* (cannot ship to a P.O. Box)

Name _____
Institution _____
Street _____
City _____ State _____ Zip _____
Country _____
Quantity _____ Fax _____
Phone: Day _____ Evening _____
E-mail Address _____

* Add \$32 for each additional shipping address

Payment and Credit Card Details

Enclosed: Personal Check _____
Institutional Purchase Order _____
Credit Card Payment Details _____

Checks must be paid in U.S. dollars and drawn on a U.S. Bank.

Credit Card: VISA Am. Exp. MasterCard
Card Number _____
Expiration Date _____
Signature: _____

Please send your order form and purchase order or prepayment made payable to:

Cenveo Reprints
4810 Williamsburg Road
Warehouse #2
Hurlock, MD 21643

FEIN #: 540157890

Invoice or Credit Card Information

Invoice Address Please Print Clearly

Please complete Invoice address as it appears on credit card statement

Name _____
Institution _____
Department _____
Street _____
City _____ State _____ Zip _____
Country _____
Phone _____ Fax _____
E-mail Address _____
Purchase Order No. _____

Cenveo will process credit cards and Cadmus Journal Services will appear on the credit card statement.

If you do not mail your order form, you may email it to cjsreprints@cadmus.com with your credit card information.

INTERNATIONAL ORDERS MUST BE PREPAID (Accompanied by Payment) IN U.S. DOLLARS

Signature _____ Date _____

Signature is required. By signing this form, the author agrees to accept the responsibility for the payment of reprints and/or all charges described in this document.

Clinical Chemistry 2017

Black and White Reprint Prices

Domestic (USA only)					
# of Pages	100	200	300	400	500
1-4	\$429	\$471	\$502	\$535	\$566
5-8	\$701	\$761	\$826	\$900	\$965
9-12	\$941	\$1,048	\$1,155	\$1,267	\$1,384
13-16	\$1,177	\$1,325	\$1,469	\$1,624	\$1,768
17-20	\$1,426	\$1,603	\$1,810	\$1,986	\$2,172
Covers	\$331	\$368	\$412	\$467	\$516
2/c Cov	\$847	\$874	\$904	\$929	\$956

International (includes Canada and Mexico)					
# of Pages	100	200	300	400	500
1-4	\$476	\$540	\$614	\$672	\$754
5-8	\$782	\$920	\$1,044	\$1,183	\$1,325
9-12	\$1,082	\$1,283	\$1,497	\$1,686	\$1,922
13-16	\$1,369	\$1,642	\$1,911	\$2,191	\$2,481
17-20	\$1,672	\$2,002	\$2,364	\$2,695	\$3,053
Covers	\$389	\$489	\$600	\$711	\$812
2/c Cov	\$847	\$874	\$904	\$929	\$956

Minimum order is 100 copies. For orders larger than 500 copies or further information, please contact Cenveo Reprints at 410-943-0629.

AACC members are eligible for a 20% discount on the above prices for reprints. To take advantage of this offer, enter your AACC member number in the space provided on this order form.

Reprint Cover

Cover prices are listed above. The cover will include the publication title, article title, and author name.

Shipping

Shipping costs are included in the reprint prices. Domestic orders are shipped via FedEx Ground service. Foreign orders are shipped via a proof of delivery air service. The shipping address printed on an institutional purchase order always supersedes.

Multiple Shipments

Orders can be shipped to more than one location. Please be aware that it will cost \$32 for each additional location.

Delivery

Your order will be shipped within 2 weeks of the journal print date. Allow extra time for delivery.

Late Order Charges

Articles more than 90 days from publication date will carry an additional charge of \$6.22 per page for file retrieval.

Color Reprint Prices

Domestic (USA only)					
# of Pages	100	200	300	400	500
1-4	\$545	\$693	\$851	\$1,002	\$1,160
5-8	\$821	\$1,007	\$1,187	\$1,379	\$1,567
9-12	\$1,078	\$1,301	\$1,530	\$1,749	\$1,973
13-16	\$1,326	\$1,586	\$1,849	\$2,116	\$2,370
17-20	\$1,589	\$1,882	\$2,188	\$2,484	\$2,773
Covers	\$331	\$368	\$412	\$467	\$516
2/c Cov	\$847	\$874	\$904	\$929	\$956

International (includes Canada and Mexico)					
# of Pages	100	200	300	400	500
1-4	\$595	\$769	\$956	\$1,135	\$1,330
5-8	\$894	\$1,141	\$1,377	\$1,616	\$1,854
9-12	\$1,193	\$1,490	\$1,798	\$2,087	\$2,387
13-16	\$1,473	\$1,831	\$2,203	\$2,556	\$2,928
17-20	\$1,772	\$2,188	\$2,612	\$3,036	\$3,451
Covers	\$389	\$489	\$600	\$711	\$812
2/c Cov	\$847	\$874	\$904	\$929	\$956

Tax Due

Residents of Virginia, Maryland, Pennsylvania, and the District of Columbia are required to add the appropriate sales tax to each reprint order. For orders shipped to Canada, please add 5% Canadian GST unless exemption is claimed.

Ordering

ALL SALES ARE FINAL; NO REFUNDS WILL BE GIVEN.

Prepayment or a signed institutional purchase order is required to process all domestic orders. International orders MUST be prepaid (accompanied by payment) in U.S. dollars. Please reference journal name and reprint number or manuscript number on your purchase order or other correspondence. You may use the reverse side of this form as a proforma invoice. Please return your order form and purchase order or prepayment to:

Cenveo Reprints
4810 Williamsburg Road
Warehouse #2
Hurlock, MD 21643

FEIN #: 540157890

Please direct all inquiries to:

Cenveo Reprints
866-487-5625 (toll free number)
410-943-0629 (direct number)
877-705-1373 (fax number)

cjsreprints@cadmus.com

Reprint Order Forms and Purchase Orders or prepayments must be received 72 hours after receipt of form.

Please return this form even if no reprints are ordered.

Proofreader's Marks

MARK	EXPLANATION	EXAMPLE
	TAKE OUT CHARACTER INDICATED	Your proof.
^	LEFT OUT, INSERT	u [^] Your proof.
#	INSERT SPACE	# Your proof. [^]
9	TURN INVERTED LETTER	Your p [^] roof.
X	BROKEN LETTER	X Your p [^] rof.
^{vv} eq#	EVEN SPACE	eq# A good proof.
○	CLOSE UP: NO SPACE	Your pro [^] gf.
tr	TRANSPOSE	tr A proof [^] good
wf	WRONG FONT	wf Your proof.
lc	LOWER CASE	lc Your p [^] roof.
≡ caps	CAPITALS	Your proof. caps <u>Y</u> our proof.
ital	ITALIC	Your proof. ital <u>Your</u> proof.
rom	ROMAN, NON ITALIC	rom Your <u>proof</u> .
bf	BOLD FACE	Your proof. bf <u>Your</u> proof.
..... stet	LET IT STAND	Your proof. stet Your proof.
out sc.	DELETE, SEE COPY	out sc. She Our proof. [^]
spell out	SPELL OUT	spell out Queen (Eliz.)
#	START PARAGRAPH	# read. [Your
no #	NO PARAGRAPH: RUN IN	no # marked. → # Your proof.
└	LOWER	└ [Your proof.]

MARK	EXPLANATION	EXAMPLE
┌	RAISE	┌ [Your proof.]
┐	MOVE LEFT	┐ Your proof.
└	MOVE RIGHT	└ Your proof.
	ALIGN TYPE	┐ Three dogs. Two horses.
==	STRAIGHTEN LINE	== Your <u>p</u> roof.
⊙	INSERT PERIOD	⊙ Your proof [^]
;/	INSERT COMMA	;/ Your proof [^]
:/	INSERT COLON	:/ Your proof [^]
;/	INSERT SEMICOLON	;/ Your proof [^]
∨	INSERT APOSTROPHE	∨ Your m [^] ans proof.
∨∨	INSERT QUOTATION MARKS	∨∨ Marked it proof [^]
=/	INSERT HYPHEN	=/ A proofmark. [^]
!	INSERT EXCLAMATION MARK	! Prove it [^]
?	INSERT QUESTION MARK	? Is it right [^]
Ⓚ	QUERY FOR AUTHOR	Ⓚ was Your proof [^] read by
[/]	INSERT BRACKETS	[/] The Smith girl [^] [^]
(/)	INSERT PARENTHESES	(/) Your proof [^] [^]
1/m	INSERT 1-EM DASH	1/m Your proof. [^]
□	INDENT 1 EM	□ Your proof
▢	INDENT 2 EMS	▢ Your proof.
▣	INDENT 3 EMS	▣ Your proof.

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia

Mary Alikian,^{1,2*} Alexandra S. Whale,³ Susanna Akiki,⁴ Kim Piechocki,⁴ Celia Torrado,¹ Thet Myint,¹ Simon Cowen,⁵ Michael Griffiths,⁴ Alistair G. Reid,^{1,2} Jane Apperley,^{2,7} Helen White,⁶ Jim F. Huggett,^{3,8} and Letizia Foroni^{2,7}

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are the cornerstone of successful clinical management of patients with chronic myeloid leukemia (CML). Quantitative monitoring of the percentage of the BCR, RhoGEF, and GTPase activating protein-ABL proto-oncogene 1, non-receptor tyrosine kinase fusion transcript *BCR-ABL1^{IS}* (%*BCR-ABL1^{IS}*) by reverse transcription-quantitative PCR (RT-qPCR) is the gold standard strategy for evaluating patient response to TKIs and classification into prognostic subgroups. However, this approach can be challenging to perform in a reproducible manner. Reverse-transcription digital PCR (RT-dPCR) is an adaptation of this method that could provide the robust and standardized workflow needed for truly standardized patient stratification.

METHODS: *BCR-ABL1* and *ABL1* transcript copy numbers were quantified in a total of 102 samples; 70 CML patients undergoing TKI therapy and 32 non-CML individuals. 3 commercially available digital PCR platforms (QS3D, QX200 and Raindrop) were compared with the platform routinely used in the clinic for RT-qPCR using the EAC (Europe Against Cancer) assay.

RESULTS: Measurements on all instruments correlated well when the %*BCR-ABL1^{IS}* was $\geq 0.1\%$. In patients with residual disease below this level, greater variations were measured both within and between instruments limiting comparable performance to a 4 log dynamic range.

CONCLUSIONS: RT-dPCR was able to quantify low-level *BCR-ABL1* transcript copies but was unable to improve sensitivity below the level of detection achieved by RT-qPCR. However, RT-dPCR was able to perform these sensitive measurements without use of a calibration curve. Adaptions to the protocol to increase the amount of RNA measured are likely to be necessary to improve the analytical sensitivity of *BCR-ABL* testing on a dPCR platform.

© 2016 American Association for Clinical Chemistry

Tyrosine kinase inhibitors (TKIs)⁹ allow successful clinical management of patients with chronic myeloid leukemia (CML) (1). Quantitative monitoring of BCR, RhoGEF, and GTPase activating protein-ABL proto-oncogene 1, non-receptor tyrosine kinase (*BCR-ABL1*)¹⁰ transcripts in peripheral blood by reverse transcription-quantitative PCR (RT-qPCR) is the gold standard strategy to evaluate response to TKI therapy. The log reduction of transcript levels at particular time points is prognostic and is used to stratify patients and to predict the risk of treatment failure (2-6). This form of monitoring has been adopted into the ELN (European Leukemia Network) guidelines. Patients are classified as good responders when the percentage of *BCR-ABL1^{IS}* (%*BCR-ABL1^{IS}*) is $\leq 10\%$ at 3 months after treatment initiation followed by $\leq 1\%$ at 6 months and $\leq 0.1\%$ at 12 months [major molecular response (MMR)] (7). Further reductions in MR from a standardized baseline [the "interna-

¹ Imperial Molecular Pathology, Imperial Healthcare Trust, Hammersmith Hospital, London, UK; ² Centre for Haematology, Faculty of Medicine, Imperial College London, London, UK; ³ Molecular and Cell Biology Team, LGC, Queens Road, Teddington, UK; ⁴ West Midlands Regional Genetics Laboratories, Birmingham Women's NHS Foundation Trust, Birmingham, UK; ⁵ Statistics Team, LGC, Queens Road, Teddington, UK; ⁶ National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK; ⁷ Clinical Haematology, Imperial College Healthcare NHS Trust, London, UK; ⁸ School of Biosciences & Medicine, Faculty of Health & Medical Science, University of Surrey, Guildford, UK.

* Address correspondence to this author at: Centre for Haematology, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Rd., London W12 0NN, UK. Fax +44-2033131507; e-mail m.alikian@imperial.ac.uk.

Received June 26, 2016; accepted November 9, 2016.

Previously published online at DOI: 10.1373/clinchem.2016.262824

© 2016 American Association for Clinical Chemistry

⁹ Nonstandard abbreviations: TKI, tyrosine kinase inhibitor; CML, chronic myeloid leukemia; RT-qPCR, reverse transcription-quantitative PCR; %*BCR-ABL1^{IS}*, percentage *BCR-ABL1^{IS}*; MMR, major molecular response; IS, international scale; cDNA, complementary DNA; dPCR, digital PCR; MIQE, minimum information for publication of quantitative real-time PCR experiments; dMIQE, digital MIQE; WMRGL, West Midlands Regional Genetics Laboratory; SNB, Sample Negative Birmingham; SNH, Sample Negative Hammersmith; LoD, limit of detection; QS3D, QuantStudio™ 3D Digital PCR System; FPR, false positivity rate.

¹⁰ Human genes: *BCR-ABL1*, BCR, RhoGEF and GTPase activating protein-ABL proto-oncogene 1, non-receptor tyrosine kinase; *ABL1*, ABL proto-oncogene 1, non-receptor tyrosine kinase; *GUSB*, glucuronidase beta.

AQ: E

AQ: E AQ: E

tional scale” (IS)] are defined as MR⁴ [detectable disease $\leq 0.01\%$ *BCR-ABL1*^{IS} or undetectable disease in complementary DNA (cDNA) with $\geq 10\,000$ *ABL1* transcripts], and MR^{4.5} (detectable disease $\leq 0.0032\%$ *BCR-ABL1*^{IS} or undetectable disease in cDNA with $\geq 32\,000$ *ABL1* transcripts) (7).

While expressing the *BCR-ABL1* transcript levels as a percentage of the total number of *ABL* transcripts on the IS has improved interlaboratory comparisons (8–9), it requires regular and cumbersome standardization. Digital PCR (dPCR) is an adaptation of the qPCR method that could enable simple, standardized quantification of nucleic acids, primarily due to its nonreliance on calibration curves (10), that could improve accuracy when measuring RNA transcripts (11). dPCR was used to quantify the ERM[®]-AD623 reference material that can be used either for the calibration of secondary “inhouse” control materials or to traceably calibrate *BCR-ABL1* copy numbers (12). dPCR can also be used directly for the absolute quantification of the *BCR-ABL1* copy numbers. In this study, we compared 3 different dPCR platforms and investigated whether they could be applied in a clinical setting to quantify *BCR-ABL1* transcripts in CML patients.

Materials and Methods

All reverse transcription, qPCR and dPCR experiments were in accordance with the minimum information for publication of quantitative real-time PCR experiments (MIQE) and digital MIQE (dMIQE) guidelines (see Table S1 in the Data Supplement that accompanies the online version of this article at <http://www.clinchem.org/content/vol63/issue2>) (13–14).

MATERIALS

The ERM-AD623 (Sigma-Aldrich) plasmid produced by the European Commission for Reference Materials (12) in addition to an inhouse control, the “Wessex” plasmid (provided by the National Genetics Regional Laboratory), were used for the performance evaluation of RT-dPCR. Both plasmids contain identical *BCR-ABL1*, *ABL1*, and glucuronidase beta (*GUSB*) sequences. Aliquots of each were stored at $-20\text{ }^{\circ}\text{C}$. Fresh dilutions of between 50 000 copies/ μL and 2 copies/ μL were prepared from the ERM plasmid, while dilutions of between 40 000 copies/ $3\ \mu\text{L}$ and 10 copies/ $3\ \mu\text{L}$ were prepared from the Wessex plasmid. The latter was routinely used for the RT-qPCR calibration curve.

CLINICAL SAMPLES

In total 102 clinical samples were analyzed in this study. Ethical approval was provided and informed consent was obtained from all patients in accordance with the Declaration of Helsinki. Archived cDNA material from 70

CML clinical samples encompassing 7 different disease levels (as measured by RT-qPCR and expressed as a percentage of *BCR-ABL1*^{IS}) were used: 20%, 10%, 1%, 0.1%, 0.01%, 0.001%, and $<0.001\%$ *BCR-ABL1* (see online Supplemental Table S2). A further 32 non-CML samples were used as negative controls. These were obtained from patients referred to the West Midlands Regional Genetics Laboratory (WMRGL) [Sample Negative Birmingham (SNB): 19 samples] and Hammersmith Hospital, London [Sample Negative Hammersmith (SNH): 13 samples] for investigation of myeloproliferative neoplasms; they were classified as non-CML based on cytogenetic and PCR tests (see online Supplemental Table S2). Negative controls from healthy volunteers were not included for practical reasons and because we felt these would add no further information to the investigation of the assay’s limit of detection (LoD).

All cDNA samples were stored at $-80\text{ }^{\circ}\text{C}$ at the Hammersmith Hospital (for a median of 2 years, range 1–7 years) following the processing of peripheral blood samples as they arrived at the laboratory according to a previously described protocol (15–16). Briefly, 20–30 mL of peripheral blood was washed in red cell lysis buffer and the total white blood cell pellet was lysed in 1.5 mL RLT buffer (Qiagen) and stored at $-80\text{ }^{\circ}\text{C}$. RNA was extracted from 350 μL of the RLT lysate using the Qiagen RNeasy Mini kit (Cat No. 74106, Qiagen) following the manufacturer’s protocol on the QIAcube robotic workstation (Qiagen). Reverse transcription was performed using 480U of M-MLV reverse transcriptase (Invitrogen, Cat No. 28025013) and 0.6 μg of random hexamers (Invitrogen, Cat No. N8080127) with 55 μL of RNA added in a 100 μL final reaction. To maintain routine feasibility, the RNA was added based on volume, with no correction for RNA concentration, and was neither evaluated for RNA quality nor DNase treated, as is normal practice in our diagnostic laboratory. Nevertheless, as part of the method development, RNA from a subset of samples was reextracted from the RLT lysates using the Qiagen RNeasy Mini plus kit (Qiagen) including an on-column DNase digestion step.

BCR-ABL1 AND ABL1 ASSAYS

Both the *BCR-ABL1* and *ABL1* assays used in this study were published by the EAC (Europe Against Cancer) initiative (17–18). For the RT-qPCR, QuantStudio[™] 3D Digital PCR System (QS3D) and QX200 platforms, both assays were modified to allow a minor groove binding (MGB) quencher to be conjugated to the 3’ end of the hydrolysis probes as described previously (19) (see online Supplemental Table S3). For the RainDrop platform, a TET (tetrachlorofluorescein) quencher was conjugated to the 3’ end of the hydrolysis probe (see online Supplemental Table S3). Assay optimization was per-

formed with primer and/or probe titrations and annealing temperature gradients for the 3 RT-dPCR platforms.

QUANTSTUDIO™ 3D dPCR SYSTEM

QS3D experiments were performed at Hammersmith Hospital. For each sample, 15 μL reactions were prepared containing 1 \times QS3D Digital PCR Master Mix, 900 nmol/L each of forward and reverse primer and 250 nmol/L of each of the probes. For analysis of both the reference material and clinical samples, 1 μL of cDNA was added to each reaction. A 2-fold dilution series (512–2 copies per reaction) and a 5000-increment dilution series (50000–1000 copies per reaction) were prepared from the reference material. In the clinical samples, triplicate RT-dPCR reactions were performed for the 4 highest disease levels (20%, 10%, 1%, and 0.1%) and 9 replicate reactions were performed for the lower disease groups and controls. For NTCs, 1 μL of nuclease-free water was added in place of cDNA.

The reaction mix was loaded into a QS3D Digital 20K chip (V1) according to the manufacturer's instructions and placed in an ABI 9700 thermocycler (Thermo Fisher Scientific). Thermocycling conditions were 96 $^{\circ}\text{C}$ for 10 min, followed by 40 cycles at 55 $^{\circ}\text{C}$ for 1 min and 98 $^{\circ}\text{C}$ for 30 s and a final extension at 55 $^{\circ}\text{C}$ for 2 min with a 16 $^{\circ}\text{C}$ hold. The chips were read using the QS3D reader and analyzed using the online Analysis Suite™ v1.0. Using the 2D scatter plots and histograms in control reactions, thresholds were set in both channels (FAM and VIC) to classify the partitions containing positive or negative amplification for the 2 targets.

QX200™ DROPLET dPCR SYSTEM

QX200 experiments were performed at LGC, London. For each sample, 20 μL reactions were prepared containing 1 \times Bio-Rad RT-dPCR SuperMix, 900 nmol/L each of forward and reverse primer, 250 nmol/L of each probe in a duplex reaction and 1 μL of cDNA. As with the QS3D, triplicate reactions were performed for samples in the 4 highest disease level categories and 9 replicate reactions were performed for the lower disease groups and controls. For NTCs, 1 μL of nuclease-free water was added in place of cDNA. Droplets were generated according to the manufacturer's instructions. Thermocycling was performed with a C1000 Touch thermocycler (Bio-Rad). Thermocycling conditions were 96 $^{\circ}\text{C}$ for 10 min, followed by 40 cycles at 94 $^{\circ}\text{C}$ for 30 s and 60 $^{\circ}\text{C}$ for 1 min. A final incubation at 98 $^{\circ}\text{C}$ for 10 min was performed for signal stabilization followed by a 12 $^{\circ}\text{C}$ hold. The ramp rate was 2 $^{\circ}\text{C}/\text{s}$. Droplets were counted and fluorescence determined using the QX200 Droplet Reader and data was analyzed using the QuantaSoft v.7.0.1 software. Using the 2D scatter plots and control reactions, thresholds were set in both channels to classify the positivity for the 2 targets.

RAINDROP DROPLET dPCR SYSTEM

RainDrop experiments were performed at the WMRGL. For each sample, 40 μL reactions were prepared containing 1 \times Applied Biosystems® TaqMan® Universal PCR Master Mix, 900 nmol/L of each primer, 200 nmol/L of each probe, 1 \times Droplet Stabilizer, and 10 μL of cDNA. Each sample was measured using duplicate reactions regardless of the disease level. For NTCs, 10 μL of nuclease-free water was added in place of cDNA. Droplets were generated using the RainDrop Source according to the manufacturer's instructions and collected in an Axygen 8 well tube strip (PN PCR-0208-C). Thermocycling was performed with a C1000 Touch thermocycler (Bio-Rad). Thermocycling conditions were 95 $^{\circ}\text{C}$ for 10 min, followed by 49 cycles at 95 $^{\circ}\text{C}$ for 15 s and 60 $^{\circ}\text{C}$ for 1 min. A final incubation at 98 $^{\circ}\text{C}$ for 10 min was performed followed by a 10 $^{\circ}\text{C}$ hold. Droplets were counted using the RainDrop Sense. Data were analyzed using the RainDrop Analyst software.

Different cDNA volumes were used on different dPCR platforms because the platforms have different reaction volumes to which different amounts of cDNA can be added with the larger reaction volume and partition number of the Raindrop platform allowing more template to be added. One microliter of cDNA on the dPCR platforms with 20 000 partitions represented a pragmatic volume that enabled an optimal concentration of *ABL1* to be measured without saturating the reactions.

QUANTITATIVE RT-qPCR

RT-qPCR experiments were performed at Hammersmith Hospital using the 7900 ABI qPCR system as described previously (19).

ABSOLUTE COPY NUMBER MEASUREMENT

Files were exported from each RT-dPCR experiment containing the number of positive partitions (k) for each assay and the total number of partitions (n) per reaction. These numbers were used to estimate the number of copies per partition (λ) using the equation $\lambda = -\ln(1 - k/n)$ (13, 20–21). The *BCR-ALB1* and *ABL* concentration in the reference materials and cDNA was calculated by converting λ to copies/ μL :

$$\text{Copies per } \mu\text{L} = \frac{\lambda}{V_p} = \frac{\text{Total reaction volume}}{\text{Added template volume}}$$

Where V_p is the partition volume (μL) as published by the manufacturer (QS3D; 0.000809 μL , QX200; 0.00085 μL , and RainDrop; 0.000005 μL). The percentage of *BCR-ABL1* was calculated as the ratio between the number of copies of *BCR-ABL1* and *ABL1*. Estimated target copy numbers per reaction were calculated by multiplying the copies/ μL by the total reaction volume.

STATISTICAL ANALYSIS

Graphing and basic statistical analysis including calculation of means, variances, SDs, CIs, and *P* values were performed using Microsoft Excel 2013, GraphPad Prism 6.0, and the R statistical programming environment (<http://www.r-project.org/>). For all statistical analyses, *P* < 0.05 was considered significant. The workflow of the statistical analysis is shown in (see online Supplemental Fig. S1).

Results

PERFORMANCE EVALUATION OF THE DUPLEX *BCR-ABL1* AND *ABL1* ASSAY BY RT-dPCR

Before the clinical analysis, validation experiments were performed using the QS3D platform. The aim was to assess the performance characteristics of a clinically applied RT-qPCR assay on an RT-dPCR platform. Dilutions of the ERM-AD623 and Wessex plasmids were used to measure and compare the 2 targets (*BCR-ABL1* and *ABL1*). Performance characteristics evaluated included the reaction set up (primer-probe concentrations, annealing temperatures, and comparison of uniplex and duplex reactions; also assessed on the other 2 digital platforms), linearity and sensitivity of the assay, and identification of bias between the 2 targets (see online Supplemental Figs. S2–S6).

Using the ERM-AD623 reference material, duplex reactions were performed with comparable results to uniplex reactions. There was no significant difference in measured concentrations (*P* = 0.385) (see online Supplemental Fig. S6A). For the investigated range, the ratio between the 2 targets showed no significant deviation from the expected ratio of 1 (*P* = 0.471; see online Supplemental Fig. S6B). Therefore, duplex experiments were used for the remainder of the study.

Linearity was maintained across the dilution range for both targets with an *R*² of 0.99 (see online Supplemental Fig. S6C). A dilution of the inhouse Wessex plasmid was set up and measurements compared to those obtained with the ERM-AD623 standard. As the concentration of the former was determined by spectrophotometry, the comparison with the ERM-AD623 reference material was used to determine if a conversion factor was needed. A highly significant systematic bias of approximately 50% was identified with the Wessex plasmid compared with the ERM-AD623 (*P* < 0.0001) (see online Supplemental Fig. S7A). A similar bias was also identified in the ERM evaluation study (12) and explained by the assignment of copy numbers assuming a single-stranded Wessex plasmid, but double stranded ERM plasmid. Using Bland–Altman Ratio plots a conversion factor of 0.46 was calculated and used for the remainder of the study. Importantly, there was no significant differ-


ence in the ratio of both targets (see online Supplemental Fig. S7B).

EVALUATION OF dPCR FOR QUANTIFICATION OF CLINICAL SAMPLES

For all clinical samples *BCR-ABL1* and *ABL1* transcripts were measured by RT-qPCR and RT-dPCR on same cDNA samples, and the percentage ratio between the 2 targets was compared. For the QS3D platform, 2 negative *ABL1* populations were observed in all samples. These were not clearly separated from each other, but obviously distinct from the positive population of partitions (see online Supplemental Fig. S8). An investigation of a subset of cDNA samples treated with and without DNase, in addition to using different *ABL1* assays, identified the cause of this problem to be genomic DNA contamination from the extraction process. Therefore, in all QS3D analyses, the additional negative populations were included in the negative partition count by adjusting the value of the fluorescent intensity threshold (see online Supplemental Fig. S8). This was not observed in experiments with the 2 droplet platforms.

ABL1 transcript copy numbers measured all 3 RT-dPCR platforms showed good correlation with RT-qPCR across all sample groups (*R*² = 0.91, 0.93, and 0.95 for QS3D, QX200, RainDrop, respectively; Fig. 1A). RT-dPCR quantification of the *BCR-ABL1* transcript copy numbers correlated well with RT-qPCR across all 3 platforms only down to ≥0.1% (*R*² = 0.85, 0.94, and 0.92 for QS3D, QX200, RainDrop, respectively; Fig. 1B). Below 0.1%, while the copy number correlations between RT-qPCR and the 3 RT-dPCR measurements were maintained, RT-dPCR produced a greater variation in the replicate measurements for each sample which was not observed for the RT-qPCR counterpart measurements. Interestingly, copy number concentrations for *BCR-ABL1* transcripts were similar across the 4 platforms whilst *ABL1* concentrations showed more variability. As %*BCR-ABL1*^{IS} is intrinsically linked to copy number concentrations for both targets, the increase in variability of the *ABL1* transcripts resulted in the %*BCR-ABL1*^{IS} frequently varying by 1 order of magnitude when compared to RT-qPCR (*R*² = 0.89, 0.92, 0.97 for QS3D, QX200, RainDrop, respectively; Fig. 1C). Furthermore, none of the platforms were able to substantially improve the sensitivity of quantification by RT-qPCR in patient samples with %*BCR-ABL1*^{IS} level <0.001%.

When using the QS3D there was good correlation down to approximately 20 copies of *BCR-ABL1* transcripts, below which a plateau was observed (Fig. 2). For quantification of the lowest 2 residual CML categories, 0.001% (where RT-qPCR returned a consistent value of 1 copy per 3 μL cDNA for all 10 patients) and <0.001% (where the qPCR results were negative), all 3 RT-dPCR



instruments detected amplification of *BCR-ABL1* targets (Fig. 2). However, the non-CML control groups also showed a positive measurement for *BCR-ABL1* that rendered the measurements obtained in the low disease groups indistinguishable from normal background noise (Fig. 2). As expected, RT-qPCR was consistently negative with no *BCR-ABL1* transcripts measured in the <0.001% category (samples in this category were chosen based on a zero reading by RT-qPCR), but detected 1–3 copies in some of the control patient groups and NTCs. The QS3D and Raindrop platforms had an appreciable false positivity rate (FPR) in the NTC reactions while only a single positive droplet was observed in 1 of the 30 NTC reactions using the QX200 platform (Fig. 2).

For the QX200 platform, the plateau was less pronounced than that observed with the QS3D. The FPR was visibly lower than those of the QS3D and Raindrop platforms. However, for the QX200, the readings obtained from the lowest 3 CML categories ($\leq 0.01\%$) were

indistinguishable from the negative control patient groups (Fig. 2). Only the Raindrop platform was able to measure % *BCR-ABL1*¹⁵ in the <0.001% range at a level higher than the FPR in the control patient groups (Fig. 2). This was possibly related to the larger volume of cDNA added to each reaction (10 μL as opposed to 1 μL). However, in the CML patient samples, the Raindrop platform did not identify any difference in the *BCR-ABL1* transcripts compared to the disease level they were assigned by RT-qPCR (0.01%, 0.001% or <0.001%; Fig. 2).

We explored the effect of differing quantities of input cDNA on sensitivity by performing 9 replicate reactions on the dPCR platforms with 20 000 partitions (i.e., using a total of 9 microliters of cDNA) for samples known to be below MMR (0.1% IS) as a mean for testing a larger volume of cDNA per sample. This increased the quantitative precision but not the sensitivity of the tests.




Fig. 2. Comparison of the *BCR-ABL1* transcript copy numbers measured per reaction in low disease level patient ($\leq 0.01\%$) and matched control samples.

The 3 low disease level patients as measured by RT-qPCR (0.01%, 0.001%, and $<0.001\%$) are shown with the matched non-CML controls (SNH and SNB) that are nominally 0% *BCR-ABL1*^{IS}. The NTC reactions were generated with water in place of cDNA. The box plots show the median and interquartile range with the whiskers showing the minimum and maximum data points from 9 replicates for each platform. The dashed horizontal line indicates zero *BCR-ABL1* transcript copies per reaction.

Discussion

In this study, we assessed the performance of 3 different RT-dPCR platforms for the future application of measuring %*BCR-ABL1*^{IS} levels in response to TKI therapy and compared each with the RT-qPCR. RT-dPCR can perform absolute quantification by counting cDNA molecules and has been reported to offer high precision and accuracy (22–25) as well as being described as “calibration-free” (26). While these strengths of RT-dPCR have facilitated its use in assigning specific values to reference materials (12, 27–28), we wanted to explore whether this method had the potential to be applied clinically to CML samples. For this purpose, we compared the gold-standard RT-qPCR test to 3 RT-dPCR instruments. For patients with a relatively high level of disease ($<0.1\%$ *BCR-ABL1*) the measurements provided by the different platforms were highly concordant. However, we identified false positivity in all 3 RT-dPCR platforms, particularly at levels $<0.01\%$, that precluded their use as a more sensitive alternative to RT-qPCR.

Taken together the data presented here suggest that RT-dPCR did not appreciably improve the sensitivity of % *BCR-ABL1*^{IS} measurement when an equal amount of cDNA was investigated on both platform types. However, the main advantage of RT-dPCR over RT-qPCR is

that it can be performed without the requirement for a calibration curve, thus offering a simpler means of ensuring interlaboratory reproducibility. In addition, RT-dPCR may offer greater confidence in the detection of low *BCR-ABL1* copy number concentrations at the limits of the current RT-qPCR technology; this could allow better distinction of patients in MR⁴ ($<0.001\%$ *BCR-ABL1*^{IS}) and MR^{4.5} ($<0.0001\%$ *BCR-ABL1*^{IS}) in patients being considered for treatment cessation trials. The expected improvement in performance and reduction in reagent costs over the next 3–5 years is therefore likely to contribute to the implementation of dPCR on a larger scale.

Normalization using the *ABL1* gene appeared to confound the results as there was generally a better agreement between RT-dPCR and RT-qPCR when measuring *BCR-ABL1* absolute values than for *ABL1* (Fig. 1). This would suggest that while *ABL1* may be a good choice of a reference gene for RT-qPCR (18), selection of an alternative reference gene following MIQE and dMIQE guidelines might be prudent if RT-dPCR is to be adopted into clinical diagnostics (13–14).

The findings of our study suggest that RT-qPCR is already working close to the physical LoD. To improve sensitivity using RT-dPCR, an increase in the amount of template would be required; this could be achieved either by the addition of more cDNA to the reaction, or by increasing the reaction volume. Other changes of potential benefit include the reduction of background noise to reduce the false positivity in the negative control sets. Further work is required to elucidate the causes of false positivity. The reproducible identification of both target molecules in the negative samples from Hammersmith hospital on both platform types after the reextraction of RNA from the original GTC lysates, confirmed that the false positivity was not caused by contamination of the original cDNA material. Certainly, RT-dPCR is at a greater risk of false-positive findings compared with RT-qPCR as the large numbers of partitions analyzed for each reaction increases the chance that a small number of these partitions will result in high fluorescence after 40 cycles of amplification. A concerted effort by the molecular testing community will be required to clarify the cause of these events.

Conclusion

The main findings of this study illustrate that RT-dPCR has a comparable performance to RT-qPCR over a 4 log dynamic range for the quantification of *BCR-ABL1*. To further improve assay sensitivity and measure MR⁴ and MR^{4.5} with confidence, changes to the upstream processing are required. The unique format of RT-dPCR, which essentially counts cDNA molecules, allows us to conclude that a major reason for this is that RT-qPCR is already measuring close to the single molecule level. Protocol modifications would therefore be required to phys-

ically increase the number of cDNA molecules made available to the PCR to increase this limit. RT-dPCR offers a powerful method to evaluate these modifications to improve RT-qPCR in the short term, however with further optimization and correct selection of reference gene, RT-dPCR could provide a reproducible alternative method to RT-qPCR in future.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

AQ: D Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

Employment or Leadership: None declared.

Consultant or Advisory Role: S. Akiki, Qiagen Haemato oncology advisory board.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: The Leuka Charity purchased the QS3D platform for this study. A.S. Whale, institutional funding by the National Measurement System; S. Cowen, work institutionally funded by the UK National Measurement System; J. Huggett, institutional funding by the UK National Measurement Office.

Expert Testimony: A. Reid, Bio Connections LLC.

Patents: None declared.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, and final approval of manuscript.

Acknowledgments: We thank Patricia Hegerich from ThermoFisher Scientific Ltd. and Dr. Adam Corner and Dr. Clair Eccleston from RainDance Technologies Ltd. for superb and outstanding technical support. We would also like to thank the Leuka Charity for purchasing the QS3D platform specifically for this study. LGC was established in 1842 as the Laboratory of the Government Chemist and, today, is an international science company and the United Kingdom's designated National Measurement Institute for chemical and bioanalytical measurement. This role combines safeguarding the quality of public science with advancing measurement research in a wide range of areas from diagnostics to food analysis.

References

- Apperley JF. Chronic myeloid leukaemia. *Lancet* 2015; 385:1447–59.
- Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. *J Clin Oncol* 2012;30:232–8.
- Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. *J Clin Oncol* 2012;30:4323–9.
- Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). *Leukemia* 2012;26:2096–102.
- Saglio G, Kantarjian HM, Shah N, Jabbour EJ, Quintas-Cardama A, Steegmann JL, et al. Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data. *Blood* 2012;120:1675.
- Cross NC, White H, Colomer D, Ehrencrona H, Foroni L, Gotardi E, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. *Leukemia* 2015;29:999–1003.
- Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood* 2013;122:872–84.
- Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. *Blood* 2006; 108:28–37.
- Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. *Best Pract Res Clin Haematol* 2009;22:355–65.
- Huggett JF, Cowen S, Foy CA. Considerations for digital PCR as an accurate molecular diagnostic tool. *Clin Chem* 2015;61:79–88.
- Sanders R, Mason DJ, Foy CA, Huggett JF. Evaluation of digital PCR for absolute RNA quantification. *PLoS One* 2013;8:e75296.
- White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, et al. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. *Leukemia* 2015;29:369–76.
- Huggett JF, Foy CA, Benes V, Emslie K, Garson JA, Haynes R, et al. The Digital MIQE Guidelines: minimum information for publication of quantitative digital PCR experiments. *Clin Chem* 2013;59:892–902.
- Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE Guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem* 2009;55:611–22.
- Foroni L, Gerrard G, Nna E, Khorashad JS, Stevens D, Swale B, et al. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia. *Am J Hematol* 2009;84:517–22.
- Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, White HE, et al. Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. *Br J Haematol* 2011;153:179–90.
- Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. *Leukemia* 2003;17: 2318–57.
- Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program. *Leukemia* 2003;17:2474–86.
- Gerrard G, Mudge K, Fosskett P, Stevens D, Alikian M, White HE, et al. Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: innovation, automation, and harmonization. *Am J Hematol* 2012;87:717–20.
- Warren L, Bryder D, Weissman IL, Quake SR. Transcription factor profiling in individual hematopoietic progenitors by digital RT-PCR. *Proc Natl Acad Sci U S A* 2006;103:17807–12.
- Warren LA, Weinstein JA, Quake SR. The Digital Array Response Curve. Department of Bioengineering, Stanford University and HHMI; Preprint March 2007.
- Weaver S, Dube S, Mir A, Qin J, Sun G, Ramakrishnan R, et al. Taking qPCR to a higher level: analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution. *Methods* 2010;50:271–6.
- Sanders R, Huggett JF, Bushell CA, Cowen S, Scott DJ, Foy CA. Evaluation of digital PCR for absolute DNA quantification. *Anal Chem* 2011;83:6474–84.
- Whale AS, Huggett JF, Cowen S, Speirs V, Shaw J, Ellison S, et al. Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. *Nucleic Acids Res* 2012;40:e82.
- Hindson CM, Chevillet JR, Briggs HA, Gallicchio EN, Ruf IK, Hindson BJ, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. *Nat Methods* 2013;10:1003–5.
- White RA, Blainey PC, Fan HC, Quake SR. Digital PCR provides sensitive and absolute calibration for high throughput sequencing. *BMC genomics* 2009;10:116.
- Corbisier P, Bhat S, Partis L, Xie VR, Emslie KR. Absolute quantification of genetically modified MON810 maize (*Zea mays* L.) by digital polymerase chain reaction. *Anal Bioanal Chem* 2010;396:2143–50.
- Haynes RJ, Kline MC, Toman B, Scott C, Wallace P, Butler JM, Holden MJ. Standard reference material 2366 for measurement of human cytomegalovirus DNA. *J Mol Diagn* 2013;15:177–85.

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

1

A—AU: Note that throughout the text edits have been made for clarity and journal style. The figures have also been edited for journal style. Please check carefully.

B—AU: Please verify the definition here of *BCR-ABL1^{IS}* as “BCR, RhoGEF, and GTPase activating protein–ABL proto-oncogene 1, non-receptor tyrosine kinase fusion transcript” or indicate further edits needed.

C—AU: Gene names have been edited so that the gene symbols and gene names used and their presentations are those approved by the HUGO Gene Nomenclature Committee (<http://www.genenames.org/index.html>) for human genes. Please check carefully to be sure that you approve of all edits, and indicate any questions or concerns.

D—AU: Please verify that the Disclosure information is presented correctly or indicate further edits needed.

E—AU: Please verify the affiliation and correspondence information or indicate further edits needed.
